Browsing Tag
Jefferies
43 posts
Is Cathay General Bancorp (Nasdaq: CATY) a quiet bank stock to watch before earnings?
Cathay General Bancorp (Nasdaq: CATY) heads into April 22 earnings near its 52-week high. Read what matters next for this regional bank stock.
Eternal (NSE: ETERNAL): Can Blinkit carry the whole company into profit?
Eternal (NSE: ETERNAL) is trading 37% off its October peak. Blinkit just hit EBITDA breakeven. Here is what retail investors need to watch before Q4 FY26 results.
AAR CORP (NYSE: AIR) locks in $450m in sole-source Air Force pallet contracts through 2032 on earnings day
AAR CORP (NYSE: AIR) wins $450M in sole-source U.S. Air Force pallet contracts to 2032. Analyst targets $119-135. Read the full strategic analysis.
Persimmon (LSE: PSN) delivers 12% completion growth and 13% profit rise as vertical integration and brand diversification sharpen competitive edge
Persimmon (PSN) reports 12% volume growth and 13% profit rise in 2025. Analyst buy consensus, 1,600p target. Read the full strategic breakdown.
Korean Air falls 10%, Lufthansa drops 7%: How the Iran conflict is hammering airline stocks worldwide
Airline stocks shed billions as U.S.-Israel strikes on Iran close Dubai, Doha and Abu Dhabi airports, cancel 19,000 flights and push oil toward historic highs.
AeroVironment (Nasdaq: AVAV) shares rebound on Space Force SCAR contract update as renegotiation talks continue
AeroVironment (AVAV) shares rise 6% as the company confirms Space Force SCAR contract talks. Read what the renegotiation means for backlog and outlook.
Why Smithfield Foods (Nasdaq: SFD) is buying Nathan’s Famous after a decade of just licensing it
Smithfield Foods to acquire Nathan’s Famous for $450M to secure brand rights and drive growth. Find out what this move means for its packaged meats strategy.
From NASA payloads to NYSE debut: What York Space Systems’ IPO reveals about space militarization
York Space Systems is going public. Find out what its IPO says about the future of U.S. space defense, agile satellites, and next-gen national security platforms.
Will Navan’s IPO be the next travel-tech breakout or just another high-burn unicorn testing public markets?
Navan targets $6.45 billion valuation in upcoming Nasdaq listing, but faces regulatory delays, valuation compression, and profitability pressures
Are investors underestimating Enanta after Jefferies’ upgrade on RSV drug zelicapavir?
Jefferies upgrades Enanta Pharmaceuticals (NASDAQ: ENTA) to Buy on zelicapavir RSV trial promise; stock outlook, financing, and market sentiment inside.